Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia 1Immunoblastic Lymphadenopathy 1

Interventions

fludarabine phosphate 23Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 20Whole-Body Irradiation 18Mycophenolic Acid 16Cyclosporine 15Etoposide 11Tacrolimus 10Busulfan 10Antilymphocyte Serum 10Methotrexate 9Melphalan 9Bortezomib 9Vorinostat 6Rituximab 6Filgrastim 6Doxorubicin 6Vincristine 5Therapeutics 5Prednisone 5Lenalidomide 5tanespimycin 4Sirolimus 4Radiotherapy 4Psychiatric Rehabilitation 4Methylprednisolone 4Everolimus 4Carboplatin 4pembrolizumab 3Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × Clofarabine × Dermatologic × Clear all
NCT00416351 2022-05-17

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
29 enrolled 15 charts
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡